Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel in previously treated advanced endometrial cancer
NCT06481592Phase 2Recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Oct 2024
- Primary completion
- May 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of lifileucel in endometrial cancer (EC), sponsored by Iovance Biotherapeutics. Started Oct 2024; status: recruiting.
02
Drugs
lifileucel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06481592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481592.